Literature DB >> 27248425

Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma.

Davide Citterio1, Antonio Facciorusso2, Carlo Sposito1, Roberta Rota1, Sherrie Bhoori1, Vincenzo Mazzaferro1.   

Abstract

IMPORTANCE: Liver resection is the treatment of choice for hepatocellular carcinoma (HCC) in well-compensated liver cirrhosis. Postoperative liver decompensation (LD) is the most representative and least predictable cause of morbidity and mortality.
OBJECTIVES: To determine the hierarchy and interaction of factors associated with the risk for LD and to define applicable risk classes among surgical candidates. DESIGN, SETTING, AND PARTICIPANTS: This retrospective review collected data from 543 patients with chronic liver disease who underwent hepatic resection for HCC from January 1, 2000, through December 31, 2013, in a tertiary comprehensive cancer center. Final follow-up was completed on January 31, 2015, and data were assessed from February 1 to 28, 2015. MAJOR OUTCOMES AND MEASURES: Preoperative prognostic factors and risk stratification for postoperative LD. Multivariate logistic regression was performed, and the independent risk factors for LD were included in a recursive partitioning analysis model. Results were validated by means of 10-fold cross-validation.
RESULTS: The analysis included 543 patients, of whom 411 (75.7%) were male, 132 (24.3%) were female, and the median age was 68 (interquartile range, 62-73) years. An independent association with LD was found for major hepatectomy (odds ratio [OR], 2.41; 95% CI, 1.17-4.30; P = .01), portal hypertension (OR, 2.20; 95% CI, 1.13-4.30; P = .01), and Model for End-Stage Liver Disease (MELD) score greater than 9 (OR, 2.26; 95% CI, 1.10-4.58; P = .02). Recursive partitioning analysis confirmed portal hypertension as the most important factor (OR, 2.99; 95% CI, 1.93-4.62; P < .001), followed by extension of hepatectomy with (OR, 2.76; 95% CI, 1.85-4.77; P = .03) and without (OR, 2.98; 95% CI, 1.97-4.52; P < .001) portal hypertension, and MELD score (OR, 1.79; 95% CI, 1.23-2.13; P < .001). Low-risk patients (LD rate, 4.9% [11 of 226]) without portal hypertension underwent minor resection with a MELD score of 9 or less; intermediate-risk patients (LD rate, 28.6% [85 of 297]) had no portal hypertension and underwent major resections or, in case of minor resections, had portal hypertension or a MELD score greater than 9; and high-risk patients (LD rate, 60.0% [12 of 20]) underwent major resection with portal hypertension. Risk-class progression paralleled median length of stay (7, 8, and 11 days, respectively; P < .001) and liver-related mortality (4.4% [10 of 226], 9.0% [27 of 297], and 25.0% [5 of 20], respectively; P = .001). A 10-fold cross-validation of the model resulted in a C index of 0.78 (95% CI, 0.74-0.82) and an overall error rate of 0.06. CONCLUSIONS AND RELEVANCE: The risk for postoperative LD after resection for HCC in chronic liver disease is associated with preoperative hierarchic interaction of portal hypertension, planned extension of hepatectomy, and the MELD score.

Entities:  

Mesh:

Year:  2016        PMID: 27248425     DOI: 10.1001/jamasurg.2016.1121

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  26 in total

1.  Pathway of care of hepatocellular carcinoma in 2017.

Authors:  Federica Invernizzi; Massimo Colombo
Journal:  Hepat Oncol       Date:  2017-06-21

Review 2.  Enlarged selection criteria for hepatocellular cancer: is the upper limit needed?

Authors:  Andrea Peloso; Graziano Oldani
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

Review 3.  Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines.

Authors:  Kyoji Ito; Nobuyuki Takemura; Fuyuki Inagaki; Fuminori Mihara; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2020-10-31

4.  Liver resections between 2014 and 2020 in the Lausanne University Hospital, Switzerland.

Authors:  Kosuke Kobayashi; Emilie Uldry; Nicolas Demartines; Nermin Halkic
Journal:  Glob Health Med       Date:  2020-10-31

5.  Hierarchical Analysis of Factors Associated with T Staging of Gastric Cancer by Endoscopic Ultrasound.

Authors:  Jung Kim; Hyunsoo Chung; Jue Lie Kim; Eunwoo Lee; Sang Gyun Kim
Journal:  Dig Dis Sci       Date:  2020-03-17       Impact factor: 3.199

6.  Expanding treatment strategies for hepatocellular carcinoma patients: postoperative adjuvant transarterial chemoembolization.

Authors:  Rodolfo Sacco; Antonio Facciorusso
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

7.  The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.

Authors:  Lei Chen; Yanqiao Ren; Tao Sun; Yanyan Cao; Liangliang Yan; Weihua Zhang; Tao Ouyang; Chuansheng Zheng
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

Review 8.  Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma.

Authors:  Takashi Kokudo; Kiyoshi Hasegawa; Chikara Shirata; Meguri Tanimoto; Takeaki Ishizawa; Junichi Kaneko; Nobuhisa Akamatsu; Junichi Arita; Nicolas Demartines; Emilie Uldry; Norihiro Kokudo; Nermin Halkic
Journal:  Liver Cancer       Date:  2019-07-26       Impact factor: 11.740

9.  A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS).

Authors:  Dimitrios Moris; Brian I Shaw; Cecilia Ong; Ashton Connor; Mariya L Samoylova; Samuel J Kesseli; Nader Abraham; Jared Gloria; Robin Schmitz; Zachary W Fitch; Bryan M Clary; Andrew S Barbas
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

10.  Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and FIB-4) Model to Predict Posthepatectomy Liver Failure Grade B-C in Patients with Hepatocellular Carcinoma.

Authors:  Wenhui Zhong; Feng Zhang; Kaijun Huang; Yiping Zou; Yubin Liu
Journal:  J Oncol       Date:  2021-04-07       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.